Review: pioglitazone does not reduce risk of mortality or cardiovascular events in type 2 diabetes

doi:10.1136/ebm.12.2.53

HOME

Author	Keyword(s)
Vol	Page
[Advanced]

Evidence-Based Medicine 2007;12:53; doi:10.1136/ebm.12.2.53
Copyright © 2007 by the BMJ Publishing Group Ltd.

This Article

	Full Text
	Full Text (PDF)
	Submit a response
	Alert me when this article is cited
	Alert me when eLetters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Add article to my folders
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via Google Scholar

Google Scholar

	Articles by Smith, D.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Smith, D.

Therapuetics

Review: pioglitazone does not reduce risk of mortality or cardiovascular events in type 2 diabetes

Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(4):CD006060.

Q In patients with type 2 diabetes, does pioglitazone reduce cardiovascular events, other adverse events, and mortality or improve health related quality of life?

Clinical impact ratings GP/FP/Primary care $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ IM/Ambulatory care $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ Cardiology $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ Endocrine $*$ $*$ $*$ $*$ $*$ $*$ ${star}$

Key Words: diabetes mellitus (type 2) • hypoglycemic agents • thiazolidinediones

The first 150 words of the full text of this article appear below.

METHODS
Data sources: Cochrane Library (issue 3, 2006), Medline, EMBASE/Excerpta Medica(to August 2006), Controlled Clinical Trials, and referencelists.

Study selection and assessment: randomised controlled trials (RCTs) $>=$ 24 weeks in duration thatevaluated pioglitazone in adults with type 2 diabetes. 22 RCTs(n = 12 466, mean age range 54–64 y) met the selectioncriteria: pioglitazone v placebo (4 RCTs) or another oral antidiabeticmedication (13 RCTs), or pioglitazone combined with other oralmedications or insulin v another combination of oral medicationsor insulin (7 RCTs). Assessment of methodological quality includedrandomisation method, allocation concealment, blinding, intentionto treat analysis, and dropouts.

Outcomes: mortality, morbidity, adverse events, health related qualityof life, costs, and metabolic control.

MAIN RESULTS
The duration of follow up was 6–12 months in all but 1RCT. Mortality and major morbidity events were reported by only1 RCT that compared pioglitazone plus other glucose loweringdrugs with placebo . . . [Full text of this article]

Donald Smith, MD, MPH

Zena and Michael A Weiner Cardiovascular Institute
New York, New York, USA